FILE PHOTO - Liam Condon, Bayer's global crop science Chief Executive Officer, attends a news conference in Sao Paulo, Brazil July 3, 2018. REUTERS/Paulo Whitaker FRANKFURT (Reuters) - The head of Bayer’s (BAYGn.DE) Crop Science unit, which combines Bayer’s legacy pesticides unit with the acquired Monsanto business, sees no merit in splitting up parent company Bayer, he told the Financial Times. When asked whether Bayer should break itself up into a standalone healthcare company and a separate agriculture business, unit head Liam Condon was quoted as saying: “That assumption would have to be that you create more value by splitting the company, which I just fail to see.” Reporting by Ludwig Burger, editing by Riham Alkousaa
Bayer's head of crop science has said he is against creating any further splits in the company. Liam Condon told the Financial Times he failed to see how a proposal to divide the company into standalone healthcare and agriculture businesses would add any value to either branch. Bayer acquired the agrochemical firm Monsanto last year.